Tenaya Therapeutics is trading 5.3% down today at $0.79 as investors react to ongoing Nasdaq minimum bid price non-compliance and recent dilution from a $60 million stock-and-warrant offering.
- The company faces continued pressure to maintain a $1.00 share price to meet Nasdaq's listing requirements, weighing heavily on investor sentiment.
- The decline appears company-specific as biotech peers are generally trading higher, highlighting concerns over the dilutive impact of recent financing.
- Market focus has shifted toward these structural challenges despite previous positive clinical data and partnership updates.